|
|
|
|
| Cat. No. 218 108 |
50 µg purified recombinant IgG, lyophilized. Albumin and azide were added for stabilization. For reconstitution add 50 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use. Antibodies should be stored at +4°C when still lyophilized. Do not freeze! |
| Applications | |
| Clone | Rb2-48 |
| Subtype | IgG1 (κ light chain) |
| Immunogen | Synthetic peptide corresponding to the amino terminal part of human Abeta-pE3 (UniProt Id: P05067) |
| Epitop |
AA 3 to 7 from human Abeta-pE3 (UniProt Id: P05067) |
| Reactivity |
Reacts with: human (P05067), mouse (P12023), rat (P08592), monkey. Other species not tested yet. |
| Remarks |
This antibody is a chimeric antibody based on the monoclonal mouse antibody 2-48. The constant regions of the heavy and light chains have been replaced with rabbit specific sequences. Therefore, the antibody can be used with standard anti-rabbit secondary reagents. The antibody has been expressed in mammalian cells. |
| Data sheet | 218_108.pdf |
|
|
Amyloid deposits, also called plaques, of Alzheimer's patients consist of several protein components like the amyloid beta-peptides (Abeta, Aβ) 1-40/42 and additional C- and N-terminally truncated and modified fragments. Very abundant are the isoaspartate (isoAsp)-Abeta and pyroglutamyl (pGlu)-Abeta peptides. The latter are formed by cyclization of the N-terminal glutamate at position 3 or 11 catalyzed by glutaminyl cyclase (QC) resulting in very amyloidogenic and neurotoxic variants of Abeta; Abeta-pE3 and Abeta pE11.
In contrast to extracellular plaques that do not perfectly correlate with Alzheimer´s disease intraneuronal Abeta accumulation and vascular Abeta deposits have gained more and more evidence to be among the crucial factors responsible for progressive neuron loss.